Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00040

Target Information
NameProstaglandin G/H synthase 1    
Type of targetSuccessful target    
Cyclooxygenase -1    
PGH synthase 1    
PHS 1    
Prostaglandin H2 synthase 1    
Prostaglandin-endoperoxide synthase 1    
DiseaseCardiovascular disease, unspecified
[ICD9: 390-459   ICD10: I00-I99]
Chronic inflammatory diseases[2]
Drug(s)BalsalazideApprovedInflammatory bowel disease[3]
BromfenacApprovedPostoperative inflammation[4]
Gamma-Homolinolenic acidApprovedDietary shortage[5][6][7]
MesalazineApprovedUlcerative colitis[8]
Salicyclic acidApprovedAcne vulgaris[9]
SalsalateApprovedRheumatoid arthritis and osteoarthritis[10][11]
SuprofenApprovedMiosis during ocular surgery[12]
BioChemical ClassOxidoreductases acting on paired donors    
EC NumberEC
PathwayArachidonic acid metabolism
Metabolic pathways
UniProt IDP23219
FunctionMay play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells.    
Target ValidationClick to Find Target Validation Information.    
QSAR ModelClick to Find Target QSAR Model.    
Inhibitor (-)-3-O-acetylspectaline[13]
(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid[14]
(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid[14]
(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid[14]
(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid[15]
(Z)-2'-des-methyl sulindac sulfide[17]
1,2-dihydro-3- (2,3,4-trimethoxyphenyl)naphthalene[18]
1- (4-[19]
1- (4-[19]
1- (4-aminosulfonylphenyl)-2-[20]
1- (4-aminosulfonylphenyl)-2-[20]
2,4'-Dimethoxy-5,3'-di- (2-propenyl)-biphenyl[22]
2- (1,1'-Biphenyl-4-Yl)Propanoic Acid[15]
2- (2,3,4-trimethoxyphenyl)-1H-indene[18]
2- (2-[23]
2- (2-Methylpropanoyl)-1,3,5-benzenetriol[24]
2- (2-methoxyphenyl)-1H-indene[18]
2- (3'-Allyl-biphenyl-4-yl)-propionic acid[25]
2- (3'-Ethyl-biphenyl-4-yl)-propionic acid[25]
2- (3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid[25]
2- (3'-Vinyl-biphenyl-4-yl)-propionic acid[25]
2- (3-Phenyl-propyl)-1,2-dihydro-indazol-3-one[26]
2- (N-[27]
2- (N-[27]
2- (p-Methylsulfonylbenzoyl)furan[28]
2-Bromoacetyl Group[29]
2-[4- (1H-Indol-5-yl)-phenyl]-propionic acid[25]
3 beta-O-acetyloleanolic acid[30]
3- (4-Methanesulfonyl-phenyl)-1-phenyl-propynone[31]
4,5-Bis (4-chlorophenyl)-1,2-selenazole[32]
4,5-Bis (4-chlorophenyl)isothiazole[33]
4,5-Bis (4-methoxyphenyl)-1,2-selenazole[32]
4,5-Bis (4-methoxyphenyl)-3H-1,2-dithiol-3-one[33]
4,5-Bis (4-methoxyphenyl)-3H-1,2-dithiole-3-thione[33]
4,5-Bis (4-methoxyphenyl)isothiazole[33]
4- (4-Chlorophenyl)-5-[33]
4- (4-Chlorophenyl)-5-p-tolyl-1,2-selenazole[32]
4- (4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one[33]
4- (4-Chlorophenyl)-5-p-tolylisothiazole[33]
4- (5-[33]
4-amino-N- (2-chlorophenyl)benzenesulfonamide[34]
4-amino-N- (4-chlorophenyl)benzenesulfonamide[34]
5- (2-1H-indenyl)-1,3-benzodioxole[18]
5- (2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline[35]
5- (4-Chlorophenyl)-4-[33]
5- (4-Chlorophenyl)-4-p-tolyl-1,2-selenazole[32]
5- (4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one[33]
5- (4-Chlorophenyl)-4-p-tolylisothiazole[33]
5- (4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole[32]
5- (4-Methoxyphenyl)-4-p-tolylisothiazole[33]
5-Phenyl-pentanoic acid benzyl-hydroxy-amide[37]
Acetic Acid Salicyloyl-Amino-Ester[15]
Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester[38]
Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester[38]
Acetic acid 2-heptylselanyl-phenyl ester[38]
Acetic acid 2-heptylsulfanyl-phenyl ester[38]
Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester[38]
Acetic acid 2-hexylsulfanyl-phenyl ester[38]
Acetic acid 2-pentylsulfanyl-phenyl ester[38]
Arachidonic Acid[29]
Flufenamic Acid[45]
Flurbiprofen Methyl Ester[29]
Gamma-Homolinolenic acid[5][6][7]
N- (1H-indazol-5-yl)acetamide[50]
N- (3-[51]
N- (3-phenoxy-4-pyridinyl)ethanesulfonamide[52]
N- (3-phenoxy-4-pyridinyl)propanesulfonamide[52]
N- (3-phenoxypyridin-4-yl)methanesulfonamide[51]
N- (3-phenylamino-4-pyridinyl)methanesulfonamide[51]
P- (2'-Iodo-5'-Thenoyl)Hydrotropic Acid[15]
Primary alcohol metabolite of celecoxib[56]
Protoporphyrin Ix Containing Co[29]
Resveratrol Potassium3-Sulfate[58]
Resveratrol Potassium4,-Sulfate[58]
Salicyclic acid[9]
alpha-Methyl-4-biphenyl-acetic acid[48]
eicosapentaenoic acid[43]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37. Epub 2004 Mar 12. To Reference
Ref 2COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000 Feb 19;355(9204):646-8. To Reference
Ref 3Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. To Reference
Ref 4Curr Med Res Opin. 2006 Jun;22(6):1133-40.Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. To Reference
Ref 5Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96. To Reference
Ref 6Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem. 2001 Oct 5;276(40):37547-55. Epub 2001 Jul 27. To Reference
Ref 7Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases. J Biol Chem. 2001 Mar 30;276(13):10358-65. Epub 2000 Dec 19. To Reference
Ref 8How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 9The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5. To Reference
Ref 10New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15. To Reference
Ref 11Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. To Reference
Ref 12Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. To Reference
Ref 13J Nat Prod. 2007 Dec;70(12):2026-8. Epub 2007 Nov 30.Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits. To Reference
Ref 14J Med Chem. 1986 Aug;29(8):1436-41.Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. To Reference
Ref 15Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 16J Med Chem. 2005 Jun 30;48(13):4312-31.2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. To Reference
Ref 17Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4. Epub 2009 Apr 23.The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. To Reference
Ref 18Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. Epub 2007 Jun 20.'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. To Reference
Ref 19Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9. Epub 2008 Jan 11.Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. To Reference
Ref 20Bioorg Med Chem. 2008 Feb 15;16(4):1948-56. Epub 2007 Nov 5.Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. To Reference
Ref 21Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. Epub 2009 Oct 20.COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. To Reference
Ref 22Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. Epub 2009 May 18.Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation. To Reference
Ref 23J Biol Chem. 2007 Jun 1;282(22):16379-90. Epub 2007 Apr 12.Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. To Reference
Ref 24J Nat Prod. 2005 Oct;68(10):1545-8.Anti-inflammatory acylphloroglucinol derivatives from Hops (Humulus lupulus). To Reference
Ref 25Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.Structure-based design of COX-2 selectivity into flurbiprofen. To Reference
Ref 26J Med Chem. 1991 Mar;34(3):1028-36.Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. To Reference
Ref 27Bioorg Med Chem. 2007 Jul 15;15(14):4876-90. Epub 2007 May 3.Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. To Reference
Ref 28J Med Chem. 2010 Sep 23;53(18):6560-71.Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. To Reference
Ref 29Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 30J Nat Prod. 2006 Jun;69(6):887-90.Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. To Reference
Ref 31Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5.Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. To Reference
Ref 32Eur J Med Chem. 2008 Jun;43(6):1152-9. Epub 2007 Sep 22.Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. To Reference
Ref 33Bioorg Med Chem. 2009 Jan 15;17(2):558-68. Epub 2008 Dec 6.Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. To Reference
Ref 34Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. Epub 2006 Oct 18.Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. To Reference
Ref 35J Med Chem. 2000 May 4;43(9):1841-51.1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. To Reference
Ref 36J Med Chem. 2004 Sep 23;47(20):4881-90.Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. To Reference
Ref 37J Med Chem. 1989 Aug;32(8):1836-42.Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis. To Reference
Ref 38J Med Chem. 1998 Nov 19;41(24):4800-18.Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. To Reference
Ref 39Bioorg. Med. Chem. Lett. 3(4):711-716 (1993) To Reference
Ref 40J Nat Prod. 2004 Nov;67(11):1777-82.Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. To Reference
Ref 41J Med Chem. 2007 Apr 5;50(7):1449-57. Epub 2007 Mar 3.NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. To Reference
Ref 42Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. To Reference
Ref 43J Nat Prod. 2001 Jun;64(6):745-9.Cox-2 inhibitory effects of naturally occurring and modified fatty acids. To Reference
Ref 44Eur J Med Chem. 2009 Sep;44(9):3798-804. Epub 2009 Apr 14.Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. To Reference
Ref 45Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. To Reference
Ref 46Biochem Pharmacol. 2002 Dec 15;64(12):1767-75.Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. To Reference
Ref 47Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. Epub 2009 Feb 27.Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. To Reference
Ref 48Bioorg Med Chem. 2010 Mar 15;18(6):2204-18. Epub 2010 Feb 8.In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. To Reference
Ref 49Bioorg Med Chem Lett. 1999 Jan 18;9(2):151-6.Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class. To Reference
Ref 50J Med Chem. 2008 Dec 25;51(24):7800-5.New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. To Reference
Ref 51J Med Chem. 2009 Oct 8;52(19):5864-71.Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. To Reference
Ref 52J Med Chem. 2004 Dec 30;47(27):6749-59.Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. To Reference
Ref 53J Med Chem. 2007 Dec 13;50(25):6367-82. Epub 2007 Nov 10.Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. To Reference
Ref 54Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) N Engl J Med. 1991 Jan 17;324(3):155-60. To Reference
Ref 55J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm. To Reference
Ref 56Bioorg Med Chem. 2008 Nov 15;16(22):9694-8. Epub 2008 Oct 5.Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies. To Reference
Ref 57Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. To Reference
Ref 58J Med Chem. 2010 Jul 8;53(13):5033-43.Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. To Reference
Ref 59J Med Chem. 2005 Oct 6;48(20):6400-8.Synthesis and antiinflammatory activity of coumarin derivatives. To Reference
Ref 60Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996) To Reference
Ref 61J Med Chem. 1998 Mar 26;41(7):1124-37.New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring. To Reference
Ref 62Bioorg Med Chem Lett. 2010 Dec 15;20(24):7349-53. Epub 2010 Oct 20.Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543